Project Details
Description
A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/11 → 12/31/23 |
Funding
- GENENTECH, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.